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Objectives. This study had three objectives: first, to
investigate the association of C-reactive protein levels
and myocardial infarction amongst men; secondly, to
study the associations of C-reactive protein levels with
cardiovascular risk factors; and thirdly, to adjust the
risk of myocardial infarction for such factors.
Design and subjects. A case±control study including
560 patients with a first myocardial infarction who
had survived at least 6 months, plus 646 control
subjects.
Results. Patients had significantly higher levels of C-
reactive protein (mean 2.2 mg L21) than control
subjects (mean 1.7 mg L21; P , 0.001). Persons in
the highest quintile of C-reactive protein had an
unadjusted 1.9-fold increased risk of myocardial
infarction compared with persons in the lowest
quintile (odds ratio 1.9, 95% CI: 1.3±2.7). C-reactive
protein was, in addition to smoking, associated with
several cardiovascular risk factors: age, obesity,
diabetes, blood pressure, triglycerides and inversely
associated to HDL cholesterol. Adjustment for these
variables, especially for total cholesterol, HDL
cholesterol and triglycerides, substantially decreased
the risk of myocardial infarction for persons in the
highest quintile of C-reactive protein, compared to
those in the lowest quintile, to 1.3 (95% CI: 0.9±1.9).
Conclusions. Our findings confirm previous reports
that C-reactive protein predicts the risk of myocardial
infarction. However, this association does not appear
to be causal, since the increase in risk can to a large
extent be explained by the presence of other
cardiovascular risk factors.
Keywords: C-reactive protein, inflammation marker,
myocardial infarction, risk factors.
Introduction
The chronic process of atherosclerosis and the acute
process of thrombosis are both involved in the
development of a myocardial infarction [1]. Athero-
sclerosis is increasingly thought to be an inflamma-
tory disease and inflammatory cells may account for
the local weakening of the atherosclerotic plaque
that results in its rupture, with the consequential
formation of a thrombus and occlusion of the artery
[2, 3]. It is possible that inflammation not only
contributes to the progression of atherosclerosis but
might also play a role in the activation of clotting
factors. C-reactive protein, a sensitive marker of
inflammatory activity, induces monocytes to express
tissue factor, the initiator of the extrinsic pathway of
coagulation [4]. Thus, inflammation may influence
the chronic as well as the acute process [1, 5].
C-reactive protein is an acute phase protein and
its production by the liver is stimulated by cytokines,
such as interleukin-6. Its plasma level is increased
up to several hundred-fold during acute inflamma-
tion [6]. It has been suggested that this protein is a
risk factor for recurrent events in patients with
angina pectoris and in patients with unstable
coronary artery disease [7±10]. The risk of elevated
C-reactive protein levels for a first myocardial
infarction has been investigated in several nested
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case±control studies with conflicting results [11±
13]. C-reactive protein is an acute-phase reactant
that may rise in response to many stimuli. There-
fore, associations with cardiovascular risk factors or
subclinical disease are likely explanations for the
observed associations of C-reactive protein and risk.
In the `Study of Myocardial Infarctions Leiden
(SMILE)', we investigated C-reactive protein levels
in 560 men with a nonfatal myocardial infarction
and 646 control subjects from the Netherlands, and
calculated risks of myocardial infarction with
increasing quintile of C-reactive protein level. We
extensively assessed the relationship of C-reactive
protein levels with other markers of risk and
adjusted the risk of myocardial infarction for
cardiovascular risk factors that were found to be
associated with C-reactive protein levels.
Materials and methods
Details of the `Study of Myocardial Infarctions
Leiden' have been described elsewhere [14]. Briefly,
patients were men below the age of 70 years, with a
first myocardial infarction that had occurred be-
tween January 1990 and January 1996. The
control group also consisted of men, frequency
matched on age to the patients, who had undergone
an orthopaedic intervention between January 1990
and May 1996 and had received prophylactic
anticoagulants for a short period after the interven-
tion. Both patients and control subjects were born in
the Netherlands. They completed a questionnaire on
smoking habits, alcohol use and the presence of
diabetes. Smoking was defined as never, former or
current. Blood pressure was measured after a rest of
at least 10 min with the person sitting in an upright
position. The body mass index was derived by
dividing weight (kilograms) by squared height
(metres), and obesity was defined at an index of
30 kg m22 or above.
Fasting blood samples were drawn from the
antecubital vein in Sarstedt Monovette tubes and
obtained between July 1994 and February 1997.
Blood in the first tube was allowed to clot and the
serum was used for measuring total cholesterol, HDL
cholesterol and triglyceride levels. Blood taken in
0.109 mol L21 trisodium citrate was centrifuged for
10 min at 3000 g at room temperature. The
citrated plasma was aliquoted in multiple tubes
and immediately stored at 2 808C. Total cholesterol
and triglyceride concentrations were measured
using enzymatic assays adapted to a Hitachi 747
(Boehringer Mannheim). High density lipoprotein
(HDL) cholesterol concentration was measured on a
Hitachi 911 (Boehringer Mannheim). C-reactive
protein levels were measured using an enzyme
linked immunosorbent assay (CRP EIA HS assay;
Kordia, the Netherlands). The within-day, between
microplate coefficient of variation was 5.2% at
0.82 mg L21 and 6.8% at 8.9 mg L21 (n = 16).
The between-day coefficient of variation was 5.3%
and 5.1% at the same respective concentrations
(n = 10).
The mean age of patients and control subjects at
the time of blood sampling was 59.1 (SE 0.4) and
57.3 (SE 0.4) years, respectively. The median time
between myocardial infarction, orthopaedic inter-
vention and blood collection was, respectively,
2.6 years and 2.9 years, with a minimum of
6 months. The closer the proximity of the event to
the time of blood collection, the higher the C-
reactive protein levels in the Cardiovascular Health
Study [12]. To evaluate whether C-reactive protein
levels decreased after myocardial infarction in our
study, we stratified the elapsed time since myocar-
dial infarction into 1-year categories. The elapsed
time since myocardial infarction did not relate to C-
reactive protein levels (Table 1).
As C-reactive protein levels were skewed, 10log-
transformation was applied. These log-transformed
values were used in the analyses and differences
between the log-transformed values were tested by
means of analysis of variance (ANOVA). However, all
values presented are converted back to geometric
means with the appropriate 95% confidence interval
(CI). P-values were considered significant at a value
, 0.05. Quintiles of C-reactive protein were defined
on the basis of the distribution of C-reactive protein
levels amongst control subjects. The lowest quintile
was used as a reference category for calculating odds
ratios (OR). Logistic regression was used to adjust for
age, smoking and other cardiovascular risk factors.
Confidence intervals of 95% (95% CI) for odds ratios
were calculated by the method of Woolf [15] or
based on the standard errors from the logistic model.
A linear test for trend [16] was used to assess any
relationship between increasing quintiles of C-
reactive protein levels and the risk of myocardial
infarction. Quintiles of total cholesterol, HDL cho-
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lesterol and triglyceride levels were defined on the
basis of the distribution amongst control subjects.
However, in the logistic regression model the three
lipid factors were included as continuous variables,
as were systolic and diastolic blood pressure.
Results
C-reactive protein level in patients with myocardial
infarction and control subjects
The mean C-reactive protein level amongst patients
with a myocardial infarction was 2.2 mg L21 (CI:
2.0±2.4) and varied between 0.1 mg L21 and
46.8 mg L21. For control subjects the mean level
was 1.7 mg L21 (CI: 1.6±1.9), with a range between
0.03 mg L21 and 115.1 mg L21. Levels in patients
were significantly higher compared with control
subjects (P , 0.001). The difference was also
evident in the absence of alcohol use, obesity or
diabetes, but not in the absence of smoking
(Table 2). C-reactive protein levels above
10 mg L21, indicating the presence of organic
disease [6], e.g. rheumatoid arthritis or colitis
ulcerosa, were found in 38 patients and 55 control
subjects. Exclusion of these persons reduced the
mean C-reactive protein levels to 1.9 mg L21 (CI:
1.8±2.1) for patients and to 1.4 mg L21 (CI: 1.3±
1.5) for control subjects (P , 0.001).
Association between C-reactive protein level and
cardiovascular risk factors
As can be seen in Fig. 1, overall C-reactive protein
levels increase gradually with age, with levels at 70±
75 years being almost twice those at 30±40 years.
At all ages, except amongst the very oldest, C-
reactive protein levels in patients were between 0.3
and 0.5 mg L21 higher than in controls.
Smokers had higher C-reactive protein levels than
never smokers, with former smokers having inter-
mediate levels, in patients as well as in control
subjects (both P , 0.001; Table 2). Alcohol use was
associated with C-reactive protein levels in patients,
with never users having higher levels compared
with regular users. However, no difference in levels
was found amongst control subjects. Obese persons
had higher levels of C-reactive protein compared to
men without this risk factor (all P , 0.05; Table 3).
Men with diabetes had higher levels compared to
those without diabetes, although this was only
significantly in patients.
Systolic and diastolic blood pressure were sig-
nificantly associated with increased C-reactive pro-
tein levels in control subjects, but not in patients.
The mean C-reactive protein level for 104 control
subjects with a systolic blood pressure of
165 mm Hg or above was 2.8 mg L21 (CI: 2.3±
3.5), compared with 1.6 mg L21 (CI: 1.4±1.7) for
those with lower levels of systolic blood pressure
(P , 0.001). The mean C-reactive protein level of
179 control subjects with diastolic blood pressure of
95 mm Hg or above was 2.0 mg L21 (CI: 1.7±2.4)
vs. 1.6 mg L21 (CI: 1.4±1.8) for those with lower
blood pressure (P , 0.05).
The C-reactive protein level was not associated
with total cholesterol levels in patients, nor in
control subjects (Table 3). However, low C-reactive
protein levels were found in control subjects and
patients in the highest quintile of HDL cholesterol. In
contrast, high levels of C-reactive protein were found
in control subjects in the highest quintile of
triglyceride levels. In patients, no consistent trend
was found in C-reactive protein levels in association
with triglyceride quintiles.
C-reactive protein level and risk of myocardial infarction,
adjusted for cardiovascular risk factors
The distribution of patients and control subjects by
quintiles of C-reactive protein levels is shown in
Table 4. The risk of myocardial infarction increased
with increasing quintiles (P , 0.001 for trend). The
unadjusted risk of myocardial infarction for men in
the highest quintile, compared with those in the
lowest quintile was 1.9-fold increased (OR 1.9, 95%
CI: 1.3±2.7). A similar trend was found for men
under the age of 50 years. Adjustment for age and
smoking led to similar patterns in the risk of
myocardial infarction; the highest risk was found
for men in the highest quintile. Adjustment for age,
total cholesterol, HDL cholesterol and triglycerides
lowered the estimated odds ratios; the unadjusted
odds ratio of 1.9 for the highest vs. the lowest
quintile of C-reactive protein, decreased to 1.3 (OR
1.3, 95% CI: 0.9±1.9). Further adjustment for
smoking, alcohol use, obesity, diabetes and blood
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pressure, several of the cardiovascular risk factors
identified as being associated with C-reactive protein
levels, did not alter these odds ratios.
To rule out the effect of outlying values we
repeated these analyses for persons who had a C-
reactive protein level lower than 10 mg L21. This
gave an unadjusted risk of myocardial infarction for
men in the highest quintile compared to those in the
lowest quintile of 2.2 (OR 2.2, 95% CI: 1.5±3.2).
Adjustments for age, total cholesterol, HDL choles-
terol and triglycerides decreased this risk to 1.4 (OR
1.4, 95% CI: 1.0±2.1), without any increased risk
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Fig. 1 C-reactive protein levels amongst patients with myocardial infarction and control subjects, by 10-year age categories.
10-year age categories
C-reactive protein level (mg L21) 30±39 40±49 50±59 60±69 70±74
Patients N 10 99 161 221 69
Mean (CI) 1.5 (0.8±3.0) 1.6 (1.3±2.0) 2.0 (1.7±2.3) 2.6 (2.2±3.0) 3.1 (2.5±3.9)
Control subjects N 46 104 181 248 57
Mean (CI) 1.1 (0.7±1.7) 1.1 (0.9±1.4) 1.4 (1.2±1.7) 2.2 (1.9±2.6) 3.1 (2.3±4.3)
P-value
ANOVA
0.53 0.02 0.01 0.16 0.97
Table 1 Elapsed time since myocardial infarction and C-reactive
protein levels
Number of years
since myocardial
infarction
Number
of
patients
C-reactive protein
level (mg L21)
mean (CI)
0.5±1 33 1.6 (1.2±2.3)
1±2 157 2.2 (1.8±2.6)
2±3 121 2.2 (1.8±2.7)
3±4 116 2.5 (2.0±3.1)
4±5 113 2.2 (1.8±2.6)
5±6 20 2.6 (1.7±4.0)
P-value ANOVA = 0.46
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for the second, third or fourth quintile compared to
the first quintile.
Discussion
This study amongst 560 men with a first myocardial
infarction and 646 control subjects shows that C-
reactive protein levels are associated with myocar-
dial infarction, with a nearly 2-fold increased risk for
persons in the highest quintile of C-reactive protein
levels, compared with those in the lowest quintile.
Many major cardiovascular risk factors such as age,
smoking, obesity and diabetes were associated with
high C-reactive protein levels. Systolic blood pres-
sure and triglyceride levels were positively asso-
ciated with C-reactive protein levels, and HDL
cholesterol was negatively associated with C-reac-
tive protein levels. This implies that the relationship
of C-reactive protein levels with myocardial infarc-
tion is confounded by these factors. Adjustment for
cardiovascular risk factors, in particular, adjustment
for total cholesterol, HDL cholesterol and triglycer-
ides, substantially decreased the risk of myocardial
infarction for men in the highest quintile to 1.3
(95% CI: 0.9±1.9) compared to men in the lowest
quintile. Thus, the association of C-reactive protein
levels with myocardial infarction can, to a large
extent, be explained by the presence of cardiovas-
cular risk factors.
C-reactive protein levels amongst patients were
higher compared with control subjects, which
corresponds to the results of the Physicians' Health
Study (PHS) [11]. Both that study and this one show
C-reactive protein as a predictor of myocardial
infarction. In our study, most of the risk associated
with C-reactive protein disappeared after adjustment
for other risk factors. This is corroborated by the
Dutch Hoorn study, a 5-year follow-up study, in
which the relative risk between C-reactive protein
and cardiovascular mortality also substantially
decreased after adjustment for several risk factors
[17]. It is also corroborated by a Danish nested case±
control study, in which C-reactive protein was not
an independent predictor of coronary heart disease
[18]. The most likely, though not only, explanation
is that C-reactive protein level predicts risk because
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Table 2 Difference in C-reactive protein levels between patients with myocardial infarction and control subjects and the association
between C-reactive protein levels and cardiovascular risk factors in both groups
Cardiovascular
risk factor
C-reactive protein (mg L21)
P-value of difference
patients and control
subjects
Patients Control subjects
Number Mean (CI)*{ Number Mean (CI)*{
Overall 560 2.2 (2.0±2.4) 646 1.7 (1.6 21.9) < 0.001
Smoking
Never 44 1.3 (0.9±1.8) 117 1.1 (1.0±1.5) 0.71
Former 362 2.1 (1.8±2.3) 314 1.7 (1.5±1.9) 0.02
Current 154 3.0 (2.6±3.5)
< 0.001
215 2.1 (1.8±2.5)
< 0.001
< 0.01
Alcohol
Never 103 2.9 (2.323.6) 64 1.7 (1.2±2.4) < 0.01
Occasionally 32 2.0 (1.4±3.1) 21 1.7 (1.0±2.9) 0.61
Regularly 425 2.1 (1.9±2.3) 561 1.7 (1.6±1.9) < 0.01
0.03 1.0
Obesity {
Absent 463 2.1 (1.9±2.3) 539 1.5 (1.4±1.7) < 0.001
Present 96 3.0 (2.4±3.7) 106 2.8 (2.3±3.4) 0.72
< 0.01 < 0.001
Diabetes
Absent 526 2.2 (2.0±2.4) 624 1.7 (1.5±1.9) < 0.001
Present 34 3.6 (2.5±5.1) 22 2.3 (1.3±4.1) 0.15
< 0.01 0.23
*P-values mentioned in this column are those of ANOVA comparing, e.g. never, former and current smokers.
{Median values of C-reactive protein level showed the same trend.
{For two persons length and weight were not available.
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it is a marker for these other risk factors. In the
MONICA Augsburg Cohort study, the relationship
between C-reactive protein levels and the incidence
of coronary heart disease events also decreased after
adjustments were made [19]. However, the effect in
the PHS, after adjustment for several identical risk
factors, remained [11]. In the analysis in which
patients were matched with control subjects on the
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Table 3 C-reactive protein levels by quintile of total cholesterol, HDL cholesterol and triglycerides amongst patients with myocardial
infarction and control subjects
C-reactive protein (mg L21)
P-value of difference
patients and control
subjects
Patients Control subjects
Quintile Range Number{ Mean (CI)*{ Number{ Mean (CI)*{
Total cholesterol (mmol L21)
1 < 5.02 85 2.3 (1.7±3.0) 128 1.8 (1.4±2.3) 0.20
2 5.02±5.57 112 2.2 (1.8±2.7) 129 1.5 (1.2±1.8) < 0.01
3 5.58±6.08 104 2.1 (1.7±2.6) 129 1.6 (1.3±2.0) 0.06
4 6.09±6.79 129 2.1 (1.7±2.5) 128 1.8 (1.5±2.2) 0.34
5 $ 6.80 126 2.4 (2.0±2.9) 131 2.0 (1.6±2.4) 0.11
0.84 0.26
HDL cholesterol (mmol L21)
1 < 1.06 197 2.8 (2.4±3.2) 128 2.4 (2.0±3.0) 0.30
2 1.06±1.22 133 2.3 (1.9±2.9) 128 2.1 (1.7±2.6) 0.49
3 1.23±1.38 109 2.1 (1.6±2.6) 130 1.5 (1.3±1.9) 0.05
4 1.39±1.61 83 1.8 (1.4±2.2) 129 1.3 (1.1±1.6) 0.06
5 $ 1.62 32 1.1 (0.8±1.5) 128 1.4 (1.1±1.7) 0.26
< 0.001 < 0.001
Triglycerides (mmol L21)
1 < 0.83 42 2.1 (1.4±3.2) 125 1.4 (1.1±1.7) 0.07
2 0.83±1.09 60 2.0 (1.5±2.8) 131 1.5 (1.2±1.9) 0.15
3 1.10±1.41 103 2.2 (1.8±2.8) 131 1.7 (1.4±2.1) 0.11
4 1.42±2.03 154 2.4 (2.0±2.9) 128 1.9 (1.6±2.3) 0.08
5 $ 2.04 198 2.2 (1.9±2.5) 130 2.1 (1.8±2.5) 0.93
0.75 0.02
*P-values mentioned in this column are those of ANOVA, comparing, e.g. C-reactive protein levels by quintiles of total cholesterol within
patients.
{Median values of C-reactive protein level showed the same trend.
{Cholesterol levels were missing for three patients and one control subject, HDL cholesterol levels for six patients and three control subjects
and triglyceride levels for three patients and one control subject.
Table 4 Risk of myocardial infarction with increasing quintile of C-reactive protein levels after adjustment for cardiovascular risk factors
(odds ratios with 95% confidence interval)
Quintile of C-reactive protein level (mg L21)
Variable adjusted for < 0.65 0.65±1.18 1.19±2.07 2.08±4.23 $ 4.24
± 1 0.9 (0.6±1.3) 1.1 (0.7±1.6) 1.7 (1.2±2.4) 1.9 (1.3±2.7)
Age 1 0.8 (0.6±1.2) 1.0 (0.7±1.5) 1.6 (1.1±2.2) 1.8 (1.2±2.6)
Age, smoking 1 0.8 (0.6±1.2) 1.0 (0.7±1.5) 1.6 (1.1±2.3) 1.8 (1.2±2.6)
Age, smoking, diabetes, alcohol, obesity, systolic
and diastolic blood pressure
1 0.8 (0.5±1.2) 1.1 (0.7±1.6) 1.7 (1.1±2.5) 1.8 (1.2±2.7)
Age, total cholesterol, HDL cholesterol and
triglycerides
1 0.8 (0.5±1.2) 0.8 (0.6±1.3) 1.2 (0.8±1.8) 1.3 (0.9±1.9)
Age, smoking, diabetes, alcohol, obesity, systolic
and diastolic blood pressure, total cholesterol,
HDL cholesterol and triglycerides
1 0.8 (0.5±1.2) 0.9 (0.6±1.4) 1.4 (1.0±2.2) 1.4 (0.9±2.1)
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presence or absence of subclinical disease, the
Cardiovascular Health Study found a nonsignificant
1.8-fold increased risk of myocardial infarction for
men in the highest quartile [12]. This is in contrast
with the Multiple Risk Factor Intervention Trial.
This latter study included only high risk men, which
probably accounts for the similar baseline levels of
C-reactive protein in patients with a myocardial
infarction and control subjects [13].
The levels of C-reactive protein differ between
studies, which is likely to be the result of different
prevalences of cardiovascular risk factors, such as
smoking, obesity, diabetes and hypertension, which
are associated with high C-reactive protein levels. It
has been suggested that C-reactive protein might
causally affect atherosclerosis or thrombosis, and
thereby increase the risk of myocardial infarction [1,
5]. Reversely, cardiovascular risk factors promote
atherosclerosis and the increase in C-reactive
protein levels in patients with myocardial infarction
could reflect the intrinsic inflammation and tissue
damage within the arterial lesions. Another possibi-
lity in this respect might be prior infection with
Helicobacter Pylori and Chlamydia Pneumoniae, which
in some studies, but not all, are associated with
coronary heart disease and various cardiovascular
risk factors, and with increased production of C-
reactive protein levels [20±23]. We must also retain
that C-reactive protein levels might be a surrogate
for cytokines. Recently, it has been suggested that C-
reactive protein might activate the complement
system, thereby promoting inflammation and
thrombosis [24]. C-reactive protein could also act
as an intermediate factor in the association of
cardiovascular risk factors and myocardial infarc-
tion. After adjustment for several cardiovascular risk
factors, the risk of myocardial infarction for men in
the highest quintile decreased to a nonsignificant
1.4-fold increased risk, supporting this option.
Residual confounding, i.e. the presence of unknown
confounders, could well explain the remaining 40%
increased risk.
We found that increasing age was associated with
increasing C-reactive protein levels. These results
are in agreement with a study amongst 303 men
aged 50±69 years from London, in which increased
levels were found with increasing age [21]. This is to
be expected, as cardiovascular risk factors are likely
to accumulate in the elderly. As C-reactive protein
levels are elevated in the presence of these risk
factors, higher levels are found in older people. This
could also explain why the difference in C-reactive
protein levels between patients and control subjects
diminishes with increasing age; control subjects
probably catch up with patients with regard to the
presence of cardiovascular risk factors. In the
Cardiovascular Health Study amongst adults aged
65 years and older, no association between age and
levels of C-reactive protein was found [25]. Another
explanation for the increase in C-reactive protein
levels with increasing age, is the increase in
prevalence of inflammatory disorders in the elderly.
Amongst patients and healthy control subjects, a
clear association existed between smoking and C-
reactive protein levels, with smokers having the
highest level, which confirms the results of other
studies [8, 11, 17±19, 26]. This agrees with the
concept that smoking causes bronchial inflamma-
tion, as C-reactive protein is a marker of inflamma-
tion and thus an elevation in levels was to be
expected. We found a strong association between
obesity and C-reactive protein levels, which confirms
the results of other studies [17±19, 21, 25±27]. It is
hypothesized that adipose tissue may play a role in
the regulation of serum C-reactive protein levels via
interleukin-6 production [27]. A positive and
negative association with, respectively, triglycerides
and HDL cholesterol, without any association of C-
reactive protein levels with total cholesterol in
control subjects, has also been reported before [21,
25].
Several points need to be made with regard to our
`Study of Myocardial Infarctions Leiden'. Our results
only apply to men, as we did not include women. In
several studies in which women were included the
results were more pronounced than amongst men
[12, 28]. However, amongst women the risk of
cardiovascular events also decreased substantially
after adjustment for several risk factors, as in our
study [29]. C-reactive protein was no longer an
independent predictor of coronary heart disease in a
follow-up study including both men and women
[18]. As C-reactive protein levels are measured at
least 6 months after the myocardial infarction, and
for most patients several years later, we cannot be
certain that they reflect the pre-myocardial infarc-
tion levels. Levels could have become elevated as a
consequence of myocardial infarction. Moreover,
our study only included individuals who had
survived a myocardial infarction. A study amongst
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188 patients with a myocardial infarction described
that patients dying within 6 months had a high rise
in C-reactive protein measured several hours after
the onset of symptoms [30]. Since we saw no effect
of time since the event, at least 6 months later,
neither is likely to have affected our results. If there
were a persistent effect as a result of the event, it
would increase the difference between patients and
controls and could not explain the absence of a
significant effect in the adjusted analysis. As a
control group, we invited persons who had under-
gone an orthopaedic intervention more than
6 months ago, the majority of whom had the
intervention more than 2 years previously. It is
very unlikely that an intervention so long ago
influenced C-reactive protein levels, especially since
most interventions were connected with a passing
injury. Both control subjects and patients were
living in the same area, and so we believe that our
control group is a good representation of the general
population from where the patients arose.
In conclusion, C-reactive protein levels are higher
amongst patients with a previous myocardial
infarction compared with controls, and an increased
risk of myocardial infarction seems apparent with
increasing quintile of C-reactive protein. As the level
of C-reactive protein is associated with several
cardiovascular risk factors, the risk of myocardial
infarction diminished after adjustment for these risk
factors and resulted in a nonsignificant 1.4-fold
increased risk for men in the highest quintile,
compared to men in the lowest quintile. Adjustment
for lipids in particular, decreased the risk to 1.3-fold.
Therefore, the association of C-reactive protein levels
with risk of myocardial infarction is largely ex-
plained by other risk factors, and the remaining
unconfounded association, if it exists, is small.
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